The Gateway® Cloning Technology is based on the site specific recombination reaction of phage lambda, an efficient biochemical process that conserves genetic information (see Figure 1). The transmission of an ORF from ORFEXPRESS™-Shuttle Clones to the Destination Vector is a one step simple and rapid operation (60 minutes at room temperature), which saves a significant amount of time and effort from the tedious, multiple step, sub-cloning process involving enzyme digestions, ligations, gel electrophoresis and purification (see Figure 2). Furthermore, a family of Destination Vectors that contain different promoters and fusion-tags that meet the distinct requirements for production and purification of desired recombinant proteins in several expression hosts is available directly from Invitrogen Corp. For more detailed information on the Gateway® Cloning Technology, please visit Invitrogen Corporation's web site at www.invitrogen.com.
Figure 1. Site specific recombination reaction of phage lambda, Click on the image to see enlarged image
Figure 2. One step transmission of an ORF from ORFEXPRESS™-Shuttle Clones to a destination vector. Click on the image to see enlarged image
The purchase of ORFEXPRESS™ Gateway® Shuttle Clones is accompanied by a limited label license under U.S. Patents 5,888,732; 6,143,557; 6,171,861; 6,270,969; 6,277,608 owned by Invitrogen, Corp. only to use the product for the internal research purposes of the purchaser. For information on purchasing a license to use the purchased product for purposes other than the internal research of the purchaser, contact the Director of Licensing at Invitrogen, Corp., 1600 Faraday Avenue, Carlsbad, CA 92008.
The trademark Gateway® is owned by Invitrogen Corporation.
